OR WAIT 15 SECS
MilliporeSigma and the International Vaccine Institute in Seoul, South Korea aim to develop more robust, scalable vaccine manufacturing processes.
MilliporeSigma, the life-science business of Merck KGaA, has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more robust, scalable vaccine manufacturing processes, the company announced on June 28, 2016. MilliporeSigma will provide funding and expertise in the areas of clarification and purification.
The IVI is a nonprofit international organization committed to the discovery, development, and delivery of safe, effective, and affordable vaccines for global public health. The new collaboration between MilliporeSigma and IVI is aimed at improving the manufacturing process to deliver greater yield, allowing higher recovery and purer vaccines. Many vaccine manufacturers in the United States and Western Europe also face high manufacturing costs, and the partnership aims to address these challenges.
"Complex manufacturing processes along with poor yield and recovery result in vaccines that are not easily affordable by resource-challenged countries," said Udit Batra, member of the executive board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. "Through our partnership with IVI, we will help create a more modern, scalable, and robust manufacturing process, which in turn will help increase access to life-saving vaccines in developing countries."
IVI was founded on the belief that the health of children in developing countries can be dramatically improved through access to new and improved vaccines, according to Jerome Kim, M.D., Director General of IVI. "We expect that our collaboration with MilliporeSigma will result in important dividends to a large population of people with unmet medical needs," said Kim. "This partnership will help us better address the vaccine needs of low- and middle-income countries and ultimately contribute to our mission."
Initially, the project will focus on a vaccine for typhoid, with the goal of applying findings to the processes for pneumococcal, meningococcal, haemophilus, staphylococcus, streptococcus B, and other conjugated polysaccharide vaccines.
With a rapidly expanding pipeline of conjugated polysaccharide vaccines, the global pharmaceutical industry needs next-generation processes for clarification and purification to ensure high-quality, affordable vaccines. Through this partnership with IVI, MilliporeSigma will apply its technologies and expertise to this challenge, which in turn will help optimize other vaccine manufacturing processes.
This initiative is part of MilliporeSigma's corporate responsibility program which focuses on expanding access to high-quality healthcare, especially in low- and middle-income countries. As part of this initiative, MilliporeSigma leverages its expertise and collaborates with strong partners to develop solutions for patients in these geographies.